Health
Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
WATERTOWN, Mass., September 29, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those wit
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2190,"height":732,"url":"https://media.zenfs.com/en/business-wire.com/60b2e53b1e52cc6fee5dd3d4c2454d42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m3.7OAKLGAyOEVkpS7FrLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/60b2e53b1e52cc6fee5dd3d4c2454d42","width":960,"height":321},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NUXdMjfndyOH38bBr4J4ng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/60b2e53b1e52cc6fee5dd3d4c2454d42","width":1200,"height":401}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥75","length":177,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Statistically Significant Improvement in Patient Global Impression of Severity Score","length":84,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Lower Hospitalization Rate for Patients Treated with Zelicapavir (1.7%) vs. Placebo (5%)","length":88,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"4- to 5-Day Faster Median Time to Undetectable Viral Load with Zelicapavir vs. Placebo","length":86,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Management to Host Conference Call and Webcast Today at 8:30 a.m. ET","length":68,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":503,"olType":false},{"type":"text","content":"WATERTOWN, Mass., September 29, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced positive topline data from RSVHR, a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of zelicapavir in outpatient adults with acute RSV infection who are at high risk of complications including the elderly and/or those with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD) or asthma. Zelicapavir, which received Fast Tra...